’s () () () Roby Zomer presents his trial plans to Proactive London.
Zomer says the the clinical trial programs planned for CimetrA™, CannEpil® and CogniCann® in 2021 are actively progressing across Australia, Israel and Brazil.
And all three trials are well funded, following the successful £6.5 million IPO fundraising and listing on the London Stock Exchange in February 2021.
Read More: MGC Pharmaceuticals update on key clinical trial plans: CimetrA, CannEpil and